| Literature DB >> 29922422 |
Setareh Sanati1, Bibi Marjan Razavi2, Hossein Hosseinzadeh3,1.
Abstract
OBJECTIVES: Metabolic syndrome, a coexisting of high blood glucose, obesity, dyslipidemia and hypertension, is an important risk factor for cardiovascular disease occurrence and mortality. Recently, there is a rising demand for herbal drugs which have less adverse effects and have shown more beneficial effects in comparison with synthetic options. Red pepper, with the scientific name of Capsicum annuum, belongs to the Solanaceae family. The lipid-lowering, antihypertensive, antidiabetic and anti-obesity effects of C. annuum have been demonstrated in several studies.Entities:
Keywords: Capsicum annuum; Cardiovascular disease; Diabetes; Dyslipidemia; Hypertension; Metabolic syndrome; Obesity; Red pepper
Year: 2018 PMID: 29922422 PMCID: PMC6000222 DOI: 10.22038/IJBMS.2018.25200.6238
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Figure 1Schematic description of traditional effects of Capsicumannuum
Figure 2Chemical structures of capsaicinoids
Summary of the effects of Capsicum annuum and capsaicin on lipid profile
| Study design | Constituents | Results | Ref |
|---|---|---|---|
| capsaicin (0.015%) for 8 weeks | ↓TG | ( | |
| red pepper (200 mg/kg aqueous extract) for 4 weeks | ↑HDL-C | ( | |
| diet including 1% red pepper powder supplement for 12 months | ↓CETP,TC,TG,LDL-C,VLDL-TG, atherogenic index | ( | |
| 8 mg capsaicin/rabbit (intubation) for 35 days | ↓plasma cholesterol, TG | ( | |
| 0.05% capsaicin for 8 weeks | ↓liver TG in normal and hypercholesterolemic rats | ( | |
| pepper-mixed pelleted food at a ratio of 1/15 for 4 weeks | ↓ TG | ( | |
| capsaicin and dihydrocapsaicin orally (4mg per birds) for 6 weeks | ↓ VLDL-C | ( | |
| six different extracts of chili pepper, dry powder (100mg) | ↑HDL | ( | |
| Human | FRPP pills for 12 weeks | ↓TC and LDL or no changes | ( |
| Human, hyperlipidemic subjects | kochujang pill (34.5 g/d) for 12 weeks | ↓TC, LDL-C | ( |
TG: triglyceride; HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; LDL-C: low density lipoprotein-cholesterol; CETP: cholesteryl ester transfer protein; VLDL: very low density lipoprotein; FRPP: fermented red pepper paste
Figure 3Schematic description showing the mechanisms of Capsicum annuum antidiabetic effects GLP1: glucagon-like peptide-1; TRPV1: transient receptor potential vanilloid subtype 1
Summary of the effects of Capsicum annuum and capsaicin on lipid profile
| Study design | Constituents | Results | Ref |
|---|---|---|---|
| dietary capsaicin | ↑ insulin sensitivity during hyperglycemic states | ( | |
| dietary capsaicin | stimulating GLP1 secretion | ( | |
| chronic dietary capsaicin | ↓ blood glucose levels | ( | |
| capsaicin (0.015%) for 4 Weeks | ↓serum levels of glucose | ( | |
| pepper-mixed pelleted food at a ratio of 1/15 for two weeks | ↓ serum glucose level in pepper-treated diabetic group | ( | |
| Human, randomized cross-over intervention study | chili meal for 4 weeks | postprandial increase in plasma glucose level in CAC group < BAB group | ( |
| Human | capsaicin (single meal) | ↑ postprandial plasma GLP1 | ( |
| Human, randomized double-blind placebo-controlled trial on pregnant women with GDM | capsaicin (5mg/dl) for 4 weeks | ↓ postprandial hyperglycemia and hyperinsulinemia | ( |
| Human, healthy subjects | capsaicin | ↑ glucose absorption from gastrointestinal tract | ( |
CGRP: calcitonin gene related peptide; NTS: nucleus tractus solitarii; ACE: angiotensin converting enzyme
Summary of the effects of Capsicum annuum and capsaicin on high blood pressure
| Study design | Constituents | Results | Ref |
|---|---|---|---|
| capsaicin (5 mg/ml) | ↓ mean systemic arterial blood pressure in | ( | |
| red pepper | release of hypotensive peptides such as substance P and CGRP | ( | |
| microinjection of capsaicin into the NTS | hypotensive and bradycardiac effect | ( | |
| capsaicin (Single dose of 50 mg/kg) on second day of postnatal life | inhibited the elevation of arterial blood pressure | ( | |
| capsaicin (15 mg/kg) for 7 months | ↓ systolic blood pressure at 4th month | ( | |
| capsaicin (Long-term and short-term treatment) | improvement of endothelium-dependent | ( | |
| red pepper | Inhibit ACE activity | ( | |
| Human, hypertensive patients with alopecia | coadministration of isoflavone and capsaicin | ↓ systolic and diastolic blood pressure | ( |
TG: triglyceride; HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; LDL-C: low density lipoprotein-cholesterol; CETP: cholesteryl ester transfer protein; VLDL: very low density lipoprotein; FRPP: fermented red pepper paste
Figure 4Schematic description showing the mechanisms of Capsicum annuum and capsaicin antidiabetic effects.
Summary of the effects of Capsicum annuum and capsaicin on obesity
| Study design | Constituents | Results | Ref |
|---|---|---|---|
| diet containing 0.014% capsaicin | ↓ visceral fat weight | ( | |
| capsaicin (addition to HFD and HCD) | ↓ weight of perineal adipose tissue | ( | |
| chitosan-capsaicin microsphere (3382 mg/kg/d) for 5 weeks | ability to control body weight > orlistat (75 mg/kg/d) | ( | |
| 0.075% capsaicin (topical application) | ↓ weight gain | ( | |
| capsaicin (2 mg/kg) | prevent adipogenesis up-regulate adiponectin expression | ( | |
| methanolic extract of | ↓ activity of G3PD | ( | |
| capsaicin | inhibit the differentiation of adipocytes | ( | |
| hot pepper seed extract (50-100-200 µg/ml) | ↓ lipid accumulation in the adipocyte | ( | |
| Human, healthy Japanese females | red pepper (added to breakfast) | ↓ protein and fat intakes at lunch time | ( |
| Human, healthy Caucasian males | red pepper (used as appetizer) | ↓ carbohydrate and energy intakes at lunch time | ( |
| Human, Japanese female | red pepper (added to high-fat meals) | ↑ BAT thermogenesis | ( |
| Human, healthy men and women | combination of capsaicin and green tea for 6 weeks | ↓ energy intake in positive energy balance | ( |
| Human, a single blind, randomized, crossover study | lunch consist of capsaicin | ↑ plasma GLP1 | ( |
| Human, clinical trial | capsaicinoids (6 mg/day) for 12 weeks | ( |
HFD: high fat diet; HCD: high carbohydrate diet; G3PD: glycerol 3 phosphate dehydrogenase; BAT: brown adipose tissue; GLP1: glucagon-like peptide-1